Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases

Debomoy Lahiri, De Mao Chen, Preeti Lahiri, Steve Bondy, Nigel H. Greig

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The aging brain shows selective neurochemical changes involving several neural cell populations. Increased brain metal levels have been associated with normal aging and a variety of diseases, including Alzheimer's disease (AD). Melatonin levels are decreased in aging, particularly in AD subjects. The loss of melatonin, which is synthesized by the pineal gland, together with the degeneration of cholinergic neurons of the basal forebrain and the deposition of aggregated proteins, such as the amyloid β peptides (Aβ), are believed to contribute to the development of cognitive symptoms of dementia. Aging and its variants, such as AD, should be viewed as the result of multiple "hits," including alterations in the levels of Aβ, metals, cholinesterase enzymes, and neuronal gene expression. Herein, we present evidence in support of this theory, based on several studies. We discuss melatonin's neuroprotective function, which plays an important role in aging, prolongation of life span, and health in the aged individual. It interacts with metals and, in some cases, neutralizes their toxic effects. Dietary supplementation of melatonin restores its age-related loss. In mice, an elevated brain melatonin significantly reduced levels of potentially toxic Aβ peptides. Thus, compensation of melatonin loss in aging by dietary supplementation could well be beneficial in terms of reducing metal-induced toxicity, lipid peroxidation, and losses in cholinergic signaling. We propose that certain cholinesterase inhibitors and the NMDA partial antagonist memantine, which are FDA-approved drugs for AD and useful to boost central nervous system functioning, can be made more effective by their combination with melatonin or other neuroprotectants. Herein, we highlight studies elucidating the role of the amyloid pathway, metals, melatonin, and the cholinergic system in the context of aging and AD. Finally, melatonin is present in edible plants and walnuts, and consuming foodstuffs containing melatonin would be beneficial by enhancing the antioxidative capacity of the organisms.

Original languageEnglish
Pages (from-to)430-449
Number of pages20
JournalAnnals of the New York Academy of Sciences
Volume1056
DOIs
StatePublished - 2005

Fingerprint

Neurodegenerative diseases
Cholinesterases
Melatonin
Amyloid
Neurodegenerative Diseases
Aging of materials
Metals
Alzheimer Disease
Cholinergic Agents
Brain
Poisons
Dietary Supplements
Life Support Care
Juglans
Memantine
Neurobehavioral Manifestations
Edible Plants
Cholinergic Neurons
Pineal Gland
Cholinesterase Inhibitors

Keywords

  • Acetylcholinesterase
  • Aging
  • Amyloid
  • Amyloid precursor protein
  • Brain
  • Cholinergic
  • Cobalt
  • Copper
  • Diet
  • Iron
  • Melatonin
  • Mercury
  • Metalloprotease
  • Metals
  • Mouse
  • Neurodegeneration
  • Neuroprotection
  • Synaptic proteins
  • Zinc

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases. / Lahiri, Debomoy; Chen, De Mao; Lahiri, Preeti; Bondy, Steve; Greig, Nigel H.

In: Annals of the New York Academy of Sciences, Vol. 1056, 2005, p. 430-449.

Research output: Contribution to journalArticle

Lahiri, Debomoy ; Chen, De Mao ; Lahiri, Preeti ; Bondy, Steve ; Greig, Nigel H. / Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases. In: Annals of the New York Academy of Sciences. 2005 ; Vol. 1056. pp. 430-449.
@article{ecbfe04af29b460691706f293b9f8b60,
title = "Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases",
abstract = "The aging brain shows selective neurochemical changes involving several neural cell populations. Increased brain metal levels have been associated with normal aging and a variety of diseases, including Alzheimer's disease (AD). Melatonin levels are decreased in aging, particularly in AD subjects. The loss of melatonin, which is synthesized by the pineal gland, together with the degeneration of cholinergic neurons of the basal forebrain and the deposition of aggregated proteins, such as the amyloid β peptides (Aβ), are believed to contribute to the development of cognitive symptoms of dementia. Aging and its variants, such as AD, should be viewed as the result of multiple {"}hits,{"} including alterations in the levels of Aβ, metals, cholinesterase enzymes, and neuronal gene expression. Herein, we present evidence in support of this theory, based on several studies. We discuss melatonin's neuroprotective function, which plays an important role in aging, prolongation of life span, and health in the aged individual. It interacts with metals and, in some cases, neutralizes their toxic effects. Dietary supplementation of melatonin restores its age-related loss. In mice, an elevated brain melatonin significantly reduced levels of potentially toxic Aβ peptides. Thus, compensation of melatonin loss in aging by dietary supplementation could well be beneficial in terms of reducing metal-induced toxicity, lipid peroxidation, and losses in cholinergic signaling. We propose that certain cholinesterase inhibitors and the NMDA partial antagonist memantine, which are FDA-approved drugs for AD and useful to boost central nervous system functioning, can be made more effective by their combination with melatonin or other neuroprotectants. Herein, we highlight studies elucidating the role of the amyloid pathway, metals, melatonin, and the cholinergic system in the context of aging and AD. Finally, melatonin is present in edible plants and walnuts, and consuming foodstuffs containing melatonin would be beneficial by enhancing the antioxidative capacity of the organisms.",
keywords = "Acetylcholinesterase, Aging, Amyloid, Amyloid precursor protein, Brain, Cholinergic, Cobalt, Copper, Diet, Iron, Melatonin, Mercury, Metalloprotease, Metals, Mouse, Neurodegeneration, Neuroprotection, Synaptic proteins, Zinc",
author = "Debomoy Lahiri and Chen, {De Mao} and Preeti Lahiri and Steve Bondy and Greig, {Nigel H.}",
year = "2005",
doi = "10.1196/annals.1352.008",
language = "English",
volume = "1056",
pages = "430--449",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases

AU - Lahiri, Debomoy

AU - Chen, De Mao

AU - Lahiri, Preeti

AU - Bondy, Steve

AU - Greig, Nigel H.

PY - 2005

Y1 - 2005

N2 - The aging brain shows selective neurochemical changes involving several neural cell populations. Increased brain metal levels have been associated with normal aging and a variety of diseases, including Alzheimer's disease (AD). Melatonin levels are decreased in aging, particularly in AD subjects. The loss of melatonin, which is synthesized by the pineal gland, together with the degeneration of cholinergic neurons of the basal forebrain and the deposition of aggregated proteins, such as the amyloid β peptides (Aβ), are believed to contribute to the development of cognitive symptoms of dementia. Aging and its variants, such as AD, should be viewed as the result of multiple "hits," including alterations in the levels of Aβ, metals, cholinesterase enzymes, and neuronal gene expression. Herein, we present evidence in support of this theory, based on several studies. We discuss melatonin's neuroprotective function, which plays an important role in aging, prolongation of life span, and health in the aged individual. It interacts with metals and, in some cases, neutralizes their toxic effects. Dietary supplementation of melatonin restores its age-related loss. In mice, an elevated brain melatonin significantly reduced levels of potentially toxic Aβ peptides. Thus, compensation of melatonin loss in aging by dietary supplementation could well be beneficial in terms of reducing metal-induced toxicity, lipid peroxidation, and losses in cholinergic signaling. We propose that certain cholinesterase inhibitors and the NMDA partial antagonist memantine, which are FDA-approved drugs for AD and useful to boost central nervous system functioning, can be made more effective by their combination with melatonin or other neuroprotectants. Herein, we highlight studies elucidating the role of the amyloid pathway, metals, melatonin, and the cholinergic system in the context of aging and AD. Finally, melatonin is present in edible plants and walnuts, and consuming foodstuffs containing melatonin would be beneficial by enhancing the antioxidative capacity of the organisms.

AB - The aging brain shows selective neurochemical changes involving several neural cell populations. Increased brain metal levels have been associated with normal aging and a variety of diseases, including Alzheimer's disease (AD). Melatonin levels are decreased in aging, particularly in AD subjects. The loss of melatonin, which is synthesized by the pineal gland, together with the degeneration of cholinergic neurons of the basal forebrain and the deposition of aggregated proteins, such as the amyloid β peptides (Aβ), are believed to contribute to the development of cognitive symptoms of dementia. Aging and its variants, such as AD, should be viewed as the result of multiple "hits," including alterations in the levels of Aβ, metals, cholinesterase enzymes, and neuronal gene expression. Herein, we present evidence in support of this theory, based on several studies. We discuss melatonin's neuroprotective function, which plays an important role in aging, prolongation of life span, and health in the aged individual. It interacts with metals and, in some cases, neutralizes their toxic effects. Dietary supplementation of melatonin restores its age-related loss. In mice, an elevated brain melatonin significantly reduced levels of potentially toxic Aβ peptides. Thus, compensation of melatonin loss in aging by dietary supplementation could well be beneficial in terms of reducing metal-induced toxicity, lipid peroxidation, and losses in cholinergic signaling. We propose that certain cholinesterase inhibitors and the NMDA partial antagonist memantine, which are FDA-approved drugs for AD and useful to boost central nervous system functioning, can be made more effective by their combination with melatonin or other neuroprotectants. Herein, we highlight studies elucidating the role of the amyloid pathway, metals, melatonin, and the cholinergic system in the context of aging and AD. Finally, melatonin is present in edible plants and walnuts, and consuming foodstuffs containing melatonin would be beneficial by enhancing the antioxidative capacity of the organisms.

KW - Acetylcholinesterase

KW - Aging

KW - Amyloid

KW - Amyloid precursor protein

KW - Brain

KW - Cholinergic

KW - Cobalt

KW - Copper

KW - Diet

KW - Iron

KW - Melatonin

KW - Mercury

KW - Metalloprotease

KW - Metals

KW - Mouse

KW - Neurodegeneration

KW - Neuroprotection

KW - Synaptic proteins

KW - Zinc

UR - http://www.scopus.com/inward/record.url?scp=29744453687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29744453687&partnerID=8YFLogxK

U2 - 10.1196/annals.1352.008

DO - 10.1196/annals.1352.008

M3 - Article

C2 - 16387707

AN - SCOPUS:29744453687

VL - 1056

SP - 430

EP - 449

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -